---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-002785"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:32:21.928302+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lipocine completes Phase 3 enrollment for oral brexanolone in postpartum depression; topline data due Q2 2026

## Summary
- 90 patients randomized in double-blind, placebo-controlled Phase 3 trial of LPCN 1154 (oral brexanolone) for PPD.
- Safety profile favorable: no discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs.
- Outpatient setting, no medical monitoring required; study incorporates FDA feedback.
- Topline efficacy and safety results expected early Q2 2026; NDA submission planned for 2026.
- LPCN 1154 could become first-line treatment for severe PPD, including elevated suicide risk.

## SEC filing metadata
- accession: 0001493152-26-002785
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226002785/0001493152-26-002785-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226002785/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-002785
- JSON: https://secwatch.observer/filing/0001493152-26-002785.json
- Plain text: https://secwatch.observer/filing/0001493152-26-002785.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.